TransMedics Q1 revenue rises 48% to $143.5 million; full-year revenue guidance raised
TransMedics reported first quarter 2025 revenue of $143.5 million, up 48% from $96.9 million a year earlier, and net income of $25.7 million, or $0.70 per diluted share, versus $12.2 million in the prior-year quarter. The company raised its full-year 2025 revenue guidance to $565 million to $585 million from the previous $530 million to $552 million range, which both headline measures and the outlook point to stronger results for shareholders.
Key points
- Q1 2025 total revenue was $143.5 million, a 48% increase from $96.9 million in Q1 2024.
- Net income was $25.7 million, or $0.70 per fully diluted share, compared with $12.2 million, or $0.35 per diluted share, a year earlier.
- Full-year 2025 revenue guidance was raised to $565 million to $585 million from $530 million to $552 million, as reported February 27, 2025; gross margin was 61% versus 62% a year earlier.
The filing
Written by AI on Nov 8, 2026, 1:49 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 08, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.